Dashboard
Manage Tickers

YSLakeShore Biopharma Co., Ltd.

Nasdaq www.ysbiopharma.com


$ 0.59 $ 0.00 (0 %)    

Wednesday, 03-Jul-2024 09:33:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 0.5696
$ 0.59
$ 0.00 x 0
$ 0.00 x 0
$ 0.59 - $ 0.59
$ 0.35 - $ 1.50
5,695
na
53.01M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ys-biopharma-changes-its-legal-name-to-lakeshore-biopharma-co-ltd-ticker-symbol-to-change-to-lsb
YS Biopharma Changes Its Legal Name To Lak...
05/24/2024 11:33:43

Effective with the opening of the trading day on May 28, 2024, the ticker symbol of the Company's ordinary shares and warra...

ys-biopharma-receives-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule
YS Biopharma Receives 180 Day Extension By...
04/29/2024 12:02:59

ys-biopharma-co-9m-2024-eps-loss-of-rmb-104-versus-rmb-271-yoy
YS Biopharma Co 9M 2024 EPS Loss Of RMB (1...
04/19/2024 11:13:28

ys-biopharma-co-9m-2024-sales-of-619m
YS Biopharma Co 9M 2024 Sales Of $61.9M
04/19/2024 11:12:34

ys-biopharma-granted-phase-i-clinical-trial-license-of-therapeutic-chronic-hepatitis-b-virus-vaccine
YS Biopharma Granted Phase I Clinical Tria...
04/18/2024 12:11:47

YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedica...

chinese-biotech-ys-biopharmas-next-gen-rabies-vaccine-non-inferior-to-approved-competitor
Chinese Biotech YS Biopharma's Next-Gen Ra...
04/09/2024 19:30:37

YS Biopharma unveils interim results from Phase 3 trial of PIKA Rabies Vaccine, meeting primary endpoints. With accelerated imm...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 12:09:53

ys-biopharma-highlights-interim-results-of-pivotal-phase-3-clinical-study-of-pika-rabies-vaccine-says-results-indicate-that-the-pika-rabies-vaccine-has-successfully-met-the-primary-endpoints-of-the-trial
YS Biopharma Highlights Interim Results Of...
04/09/2024 12:09:00

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
03/28/2024 12:06:10

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 21:31:07

ys-biopharma-appoints-six-new-members-to-its-board-effective-february-13-2024-names-ajit-shetty-as-chairperson
YS Biopharma Appoints Six New Members To I...
02/14/2024 12:52:23

The six new directors are: Dr. Yuntao Cui; Dr. Jin Wang; Mr. Henry Chen; Mr. Haitao Zhao; Mr. Pierson Yue Pan; and Ms. Brenda C...

ys-biopharma-discloses-40m-private-placement-financing-at-a-purchase-price-of-041986-per-share
YS Biopharma Discloses $40M Private Placem...
02/09/2024 11:36:10

ys-biopharma-unit-received-letter-claiming-breach-of-financial-covenant-related-to-ebitda-margin-r-bridge-urged-the-unit-to-prepay-loan-of-447m-by-january-31-citing-material-adverse-effect
YS Biopharma Unit Received Letter Claiming...
01/26/2024 11:33:41

-6-K

ys-biopharma-reports-h1-loss-per-shae-of-026-net-loss-243m
YS Biopharma Reports H1 Loss Per Shae Of $...
01/22/2024 22:08:20

As of September 30, 2023, the company had cash and cash equivalents of RMB259.9 million ($36.2 million), compared with RMB370.4...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
12/26/2023 21:31:08

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
12/26/2023 17:31:10

ys-biopharma-responds-to-unauthorized-pr-regarding-extraordinary-general-meeting-says-yi-zhang-is-not-the-chairperson-and-does-not-have-any-authority-to-call-general-meeting-of-shareholders
YS Biopharma Responds To Unauthorized PR R...
12/20/2023 21:37:25

The company said its filing on Form 6-K with the U.S. Securities and Exchange Commission on December 12, 2023 explicitly states...

noble-capital-markets-initiates-coverage-on-ys-biopharma-co-with-outperform-rating-announces-price-target-of-525
Noble Capital Markets Initiates Coverage O...
11/13/2023 17:06:15

Noble Capital Markets analyst Gregory Aurand initiates coverage on YS Biopharma Co (NASDAQ:YS) with a Outperform rating and ...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
10/05/2023 21:32:13

stocks-that-hit-52-week-lows-on-tuesday
Stocks That Hit 52-Week Lows On Tuesday
10/03/2023 18:37:58

  On Tuesday, 647 companies set new 52-week lows.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)